MELBOURNE, Australia,
April 29, 2024 /PRNewswire/ --
Prota Therapeutics' CEO Professor Mimi Tang has been honoured in the prestigious
2024 BioMelbourne Network Women in Leadership Awards. Professor
Tang's exceptional work as a lead researcher for the Murdoch
Children's Research Institute (MCRI) and her groundbreaking
contributions to the understanding and treatment of food allergies
have earned her this year's Distinguished Leadership Award.
As the CEO of Prota Therapeutics, Professor Tang has
demonstrated remarkable vision and resilience in advancing the
company's mission to provide transformative treatments for food
allergies. Under her guidance, Prota Therapeutics has made
significant strides in developing novel immunotherapies that have
the potential to revolutionize the way food allergies are managed
and treated. The company has recently secured US$21 million to finance a Phase 3 clinical
investigation of its PRT120 oral therapy for peanut allergy.
"Receiving the 2024 Distinguished Leadership Award from the
BioMelbourne Network is a tremendous honour. I am grateful for this
recognition and would like to acknowledge the support of my teams
at Prota Therapeutics and Murdoch Children's Research Institute.
This award reaffirms my commitment to pushing the boundaries of
scientific innovation and making a meaningful impact on the lives
of patients suffering from food allergies", celebrated
Professor Mimi Tang.
Professor Tang's leadership extends beyond her role as CEO of
Prota Therapeutics. As a globally recognized leader in the
life sciences industry, she has made significant contributions to
academia, clinical practice, and biotechnological innovation. Her
pioneering work at the Murdoch Children's Research Institute has
led to paradigm shifts in clinical management of food allergies and
has inspired new therapeutic approaches that are making a
difference in the lives of patients worldwide.
At MCRI, Professor Tang also led the development of a mobile app
called AllergyPal, an award-winning free digital
management platform for allergy and anaphylaxis. Designed to
support families in managing their child's food allergies,
AllergyPal provides ready access to a child's allergy plan,
interactive guidance on how to manage allergic reactions in an
emergency and a way for parents to leave individualised
instructions on their preferred approach to allergen avoidance. The
app was created in collaboration with Allergy & Anaphylaxis
Australia and the Australasian Society of Clinical Immunology and
Allergy. Professor Tang remains a director on the board of
AllergyPal.
"Professor Tang's innovative approach to food immunotherapy
has not only revolutionised treatment methods but has also
significantly improved the health and wellbeing of children living
with food allergy. The impact of her work goes beyond the
laboratory and clinical settings; it directly translates into
meaningful outcomes for children and their families, and, once
approved, will ultimately offer children a path to remission and a
life free from the burden of severe food allergies", said
Allergy & Anaphylaxis Australia CEO Maria Said AM.
Professor Tang's pioneering efforts have reshaped the landscape
of allergy management by making remission of allergies a tangible
reality. Mimi's scientific achievement is evidenced by her
extensive publication record with over 350 peer-reviewed articles,
securing $72 million in research
grant funding, and earning recognition as one of the top 1% highly
cited researchers in Immunology.
The BioMelbourne Network Women in Leadership Awards celebrate
individuals who demonstrate exceptional leadership qualities,
contribute significantly to the health industry, and inspire
positive change within the community. Professor Mimi Tang's recognition as this year's recipient
of the Distinguished Leadership Award is a testament to her
profound impact on the industry and her unwavering commitment to
innovation and excellence.
About Prota Therapeutics
Prota Therapeutics is an Australian proprietary limited,
privately-held biotech company established in 2016 to develop and
commercialize novel oral immunotherapy treatments for food allergy.
Prota holds intellectual property covering the proprietary food
immunotherapy technology developed at the MCRI. The company is, in
part, a OneVentures' Healthcare Fund III investment. This fund was
established with investment in part from the Australian
Commonwealth Government through the BioMedical Translation Fund
initiative. Prota Therapeutics has its headquarters in Melbourne, Australia. For more information
please visit: https://protatherapeutics.com/.
About Murdoch Children's Research Institute:
Murdoch Children's Research Institute is the largest child
health research institute in Australia committed to making discoveries and
developing treatments to improve child and adolescent health in
Australia and around the world.
They are pioneering new treatments, trialling better vaccines and
improving ways of diagnosing and helping sick babies, children and
adolescents. It is one of the only research institutes in
Australia to offer genetic testing
to find answers for families of children with previously
undiagnosed conditions.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/prota-therapeutics-ceo-mimi-tang-honoured-at-biomelbourne-networks-women-in-leadership-awards-2024-302129874.html
SOURCE Prota Therapeutics